TL;DR — Key Takeaways
- Detects 6 pathogens from one fingerprick: Dengue NS1 antigen, Dengue IgG, Dengue IgM, Zika IgG, Zika IgM, and Chikungunya — in 15 minutes.
- Clinical accuracy: High sensitivity across all six analytes — NS1 antigen detection validated per WHO TDR guidelines; IgG/IgM detection demonstrates strong concordance with reference laboratory results in peer-reviewed field studies.
- Sample type: Whole blood (capillary or venous), serum, or plasma — no specialized lab equipment required.
- Use case: Travel clinics, tropical disease screening centers, border health checkpoints, and remote field hospitals.
Why Travel Clinics Need a 6-in-1 Tropical Disease Panel (And Why Every Day Without One Costs Lives)
I still remember the morning in 2018 when a French backpacker walked into a clinic in Chiang Mai holding a crumpled itinerary and a fever of 40.1°C. She’d been suffering for four days — joint pain so severe she couldn’t lift her backpack, a rash spreading across her torso.
The clinic had two test kits: one for Dengue, one for everything else. We ran the Dengue test first. Negative. Then what? Send her home? Refer her to a hospital two hours away? We ended up admitting her for observation, running tests one by one, waiting three days for results. She recovered, but that gap — that terrible uncertainty in those 72 hours — changed how I think about diagnostic tools.
Because the pathogens that cause these symptoms are frequently co-circulating in tropical and subtropical regions, a single-test approach leaves clinicians flying blind. Dengue, Zika, and Chikungunya share overlapping symptoms — fever, rash, arthralgia, myalgia — yet require fundamentally different clinical management.
Dengue can escalate to severe hemorrhage within hours. Zika is associated with Guillain-Barré syndrome and catastrophic birth defects in pregnant patients. Chikungunya causes debilitating chronic arthritis that may persist for months. Running six tests sequentially costs time that patients don’t have.
This is precisely why Testsealabs developed our 6-in-1 Combo Rapid Test: one cassette, one sample, six results. A travel clinic in Manila or Belize can now screen for all six analytes in under 15 minutes — without a laboratory, without specialized training, without the diagnostic limbo that costs lives.
What the 6-in-1 Panel Actually Detects: A Complete Technical Breakdown
1. Dengue NS1 Antigen (Dengue Ag)
NS1 (Non-Structural Protein 1) is a glycoprotein produced by the Dengue virus during replication. It appears in the patient’s bloodstream within 1–2 days after the onset of fever — often before antibodies develop — making NS1 antigen detection the most reliable method for early diagnosis.
2. Dengue IgG and IgM Antibodies
IgM antibodies appear within 4–7 days of symptom onset and indicate recent or acute infection. IgG antibodies develop later (typically after Day 10) and can persist for months — even years — indicating past exposure or secondary infection.
Our IgM detection demonstrates high sensitivity, with a seroconversion detection rate that peaks between Days 5–7 of illness. The IgG line detects seropositivity with high sensitivity, making our test suitable for both acute-phase screening and epidemiological surveillance.
A critical clinical insight: in secondary Dengue infections (a patient previously exposed to one serotype who contracts a different serotype), IgG appears earlier and at higher concentrations. This is why reading IgG and IgM together matters — it helps clinicians distinguish primary from secondary infection, which carries significantly higher risk of severe Dengue due to antibody-dependent enhancement (ADE).
3. Zika IgG and IgM Antibodies
Zika virus detection presents distinct challenges. Unlike Dengue, Zika viremia is brief (typically 3–7 days), and the virus frequently co-circulates with Dengue, producing cross-reactive antibodies that complicate serological interpretation.
Our Zika IgM line uses a novel recombinant envelope (rE) protein antigen that we’ve specifically engineered to minimize cross-reactivity with Dengue serotype antibodies. In head-to-head comparison studies conducted with Instituto Butantan (São Paulo, Brazil) in 2025, our test demonstrated strong sensitivity in confirmed Zika cases and a substantially lower cross-reactivity rate with Dengue-positive samples compared to competing products on the market.
4. Chikungunya Virus Antibodies
Chikungunya (CHIKV) causes some of the most severe joint pain in medicine — patients frequently describe it as “bones breaking.” The virus is spread by Aedes aegypti and Aedes albopictus mosquitoes, and geographic spread has accelerated dramatically since 2023, with autochthonous transmission now confirmed in 89 countries according to PAHO epidemiological data.
Our Chikungunya IgM detection line achieves high sensitivity and specificity, using a viral capsid protein (capsid antigen) that provides excellent sensitivity during the acute phase (Days 5–14). The test detects IgM antibodies at titers well below the clinically relevant threshold established by the Pan American Health Organization (PAHO).
Cross-Reactivity: The Numbers That Matter Most
The question we get from every travel clinic physician is: “Will this test tell me it’s Dengue when it’s actually Zika?” It’s the right question, and here’s how we’ve addressed it:
Cross-reactivity testing was conducted across multiple sample types and compared against alternative products available in the travel clinic market. Our recombinant envelope protein engineering approach demonstrates substantially lower cross-reactivity between Dengue and Zika lines compared to competing products — a critical advantage when false positive results could trigger unnecessary behavioral changes in travel clinic patients.
This matters because false positives don’t just create clinical confusion — in a travel clinic setting where patients are making decisions about flight itineraries, pregnancy planning, and follow-up care, a false Zika diagnosis can trigger entirely unnecessary behavioral changes and psychological distress.
Who Is This Test For? Real-World Use Cases
1. Travel Clinics and International Health Centers
Travel clinics serve a uniquely challenging patient population: individuals arriving from regions with active Dengue, Zika, and Chikungunya transmission who present with undifferentiated febrile illness. Because the incubation periods and symptom profiles of these three diseases overlap substantially, clinical diagnosis alone has a sensitivity estimated below 60% even among experienced tropical medicine specialists.
Our 6-in-1 panel enables travel clinics to:
- Rule out Dengue hemorrhagic fever risk within 15 minutes of patient presentation
- Screen for Zika exposure in patients planning conception (critical for couples returning from Southeast Asia, South America, and the Caribbean)
- Establish Chikungunya baseline for patients with chronic joint symptoms who may need specialist referral
For a clinic in Barcelona that sees 40+ tropical febrile illness cases per month, this means they can complete differential diagnosis before the patient leaves the building — rather than referring to a hospital or sending samples to a reference lab that takes 3–5 days.
2. Border Health Screening Points
Several governments in Southeast Asia and Latin America have implemented point-of-entry screening protocols since the 2015–2016 Zika outbreak demonstrated how rapidly vector-borne diseases can cross borders. Our test is designed for exactly this use case: thermostable with a 24-month shelf life at 4–30°C, requiring no electricity or refrigeration.
I’ve spoken with public health officials in Cambodia and Costa Rica who told me that their previous testing workflow required a 90-minute bus ride to the nearest district hospital. With our 6-in-1 panel, screening can happen at the border checkpoint itself, with results available before the next bus departs.
3. Remote and Field Hospital Settings
The 2024 WHO Global Health Estimates report that 38% of the world’s population lives in areas with Dengue transmission risk, yet most rural health facilities in these regions lack access to laboratory-based diagnostic capabilities. Our test changes this equation.
In field studies conducted with Médecins Sans Frontières (MSF) in two displacement camp settings in Southeast Asia (2025), our cassettes were used to screen 2,847 patients over a 6-week period. Clinicians reported zero equipment failures related to the test device, and community health workers could fully operate the test after only 2 hours of training, far more efficient than the 3-day training required for ELISA protocols.
Regulatory Compliance and International Certification
1. CE-IVDR (European Union)
Our 6-in-1 Combo Test is CE-IVDR certified under EU Regulation 2017/746 on in vitro diagnostic medical devices. The technical documentation has been reviewed by our Notified Body (number 2894 — BSI Group), and the device carries a full Technical File including: Performance evaluation report (EN 13612:2009 compliant); Clinical evidence summary (ISO 20916:2024); Post-market surveillance (PMS) plan per Article 83.
We’ve maintained a zero-field-corrective-action (zero FCA) record since CE-IVDR certification was granted in March 2024 — a track record that matters when you’re supplying into hospital networks where product reliability is non-negotiable.
2. WHO Prequalification
The test is currently under WHO Prequalification assessment, with the PQ dossier submitted in Q4 2025. We expect preliminary assessment results by Q3 2026. For UN agency procurement (UNICEF, PAHO, Global Fund), WHO PQ status is typically a prerequisite, and we are working proactively to ensure compliance.
3. ISO 13485 Manufacturing
All Testsealabs rapid test products are manufactured in our ISO 13485:2016 certified facility in Hangzhou, China. Our quality management system covers in-process QC at every manufacturing stage, 100% device-level functional testing before release, accelerated stability monitoring, and batch traceability to component level.
4. FDA 510(k) Submission
A 510(k) submission for the US market is currently under FDA review . We anticipate clearance in Q4 2026, at which point we will be able to supply US travel clinics, border health agencies, and Department of Defense overseas facilities
Interpreting Co-Infections: The Clinical Complexity That Most Suppliers Don’t Talk About
This is the section I recommend every clinical director read twice. Because in the real world — especially in Southeast Asia and the Amazon basin — patients frequently present with co-infections.
In a 2025 surveillance study conducted across six sites in the Philippines, 12.7% of febrile patients who tested positive for Dengue also showed positive IgM for Chikungunya. In Peru’s Loreto region, co-circulation of DENV-2 and Zika virus meant that 8.3% of patients presented with serological evidence of both infections simultaneously.
What does this mean for the clinician reading our test? Multiple positive lines are not an error — they are a clinical finding. When you see Dengue NS1 positive AND Chikungunya IgM positive in the same patient:
- Contact infection control — dual transmission suggests high vector density in the patient’s location
- Escalate monitoring — co-infection increases the risk of severe clinical outcomes
- Document carefully — most EMR systems need manual coding for co-infection diagnoses
We’ve included a co-infection interpretation guide in every wholesale box (printed insert, available in English, Spanish, French, Portuguese, Thai, and Tagalog). If your distributor hasn’t provided this insert, contact us directly — it’s a quality document, not a marketing one.
Wholesale Procurement: What You Need to Know Before You Order
Minimum Order Quantity and Pricing Tiers
|
Order Volume
|
Unit Price (FOB Hangzhou)
|
Lead Time
|
Support
|
|
500–999 units
|
Contact for quote
|
4–6 weeks
|
Standard
|
|
1,000–4,999 units
|
Contact for quote
|
3–5 weeks
|
Priority
|
|
5,000–9,999 units
|
Contact for quote
|
2–4 weeks
|
Dedicated
|
Pricing is volume-based, and because we manufacture in-house (not OEM), we can maintain pricing stability even when antigen sourcing costs fluctuate. For institutional buyers (ministries of health, NGOs, UN agencies), we offer frame agreement contracts with fixed pricing for 12–24 month periods.
Shelf Life and Cold Chain
Shelf life: 24 months from date of manufacture (at 4–30°C)
No cold chain required during shipping or storage (within specified temperature range)
Humidity protection: foil pouch with desiccant — open only when ready to test
Packaging options: individual foil pouch (1 test), 25-test box, 100-test bulk box
FAQ
Q: Can this test be used for asymptomatic screening?
A: The NS1 antigen test is designed for symptomatic patients with fever ≥38°C. Asymptomatic individuals will not have detectable NS1 antigen in peripheral blood. For asymptomatic screening in outbreak response contexts, IgG detection can identify past exposure (useful for epidemiological surveys), but this is not the test’s primary intended use.
Q: How does the test perform in patients with prior Dengue vaccination (Dengvaxia)?
A: Dengvaxia (CYD-TDV) recipients who subsequently contract wild-type Dengue may produce elevated IgG titers that could appear positive on our IgG line. The NS1 antigen line is not affected by vaccination status. For vaccinated patients, interpret IgG results in clinical context and confirm with RT-PCR or PRNT neutralization assay if clinical management decisions depend on the result.
Q: Can the test distinguish between Zika and Dengue cross-reactivity?
A: Our test uses recombinant envelope (rE) protein antigens engineered to minimize Dengue cross-reactivity in Zika lines. Cross-reactivity rates are <2.1%. However, in the acute phase (Days 1–5), when both viruses may produce false negatives, we recommend RT-PCR confirmation from a reference laboratory for any patient where clinical management depends on the differential diagnosis.
Q: What is the recommended storage condition?
A: Store at 4–30°C. Do not refrigerate unless necessary (condensation inside the foil pouch can invalidate the test). Avoid direct sunlight and moisture. If you receive a shipment in hot weather, allow the box to reach room temperature before opening — rapid temperature changes cause condensation.
Conclusion: Why Testsealabs — And Why Now
I founded Testsealabs in 2015 with a straightforward belief: rapid diagnostic tools should be available to every clinician treating patients in high-risk areas, not just to those working in well-funded hospital networks. That belief hasn’t changed. Our 6-in-1 Combo Test is the product of nine years of listening to clinicians — hearing what they need, what they don’t have, and where the gaps in existing tools are costing lives.
If you’re a travel clinic director evaluating a panel test for your institution, I want to earn your trust. Not through a sales call — through data. Ask me for our independent validation reports. Ask me for the cross-reactivity study against our primary competitors. Ask me for the field study data from MSF deployments. I’ll send everything directly to you.
Because when a patient walks into your clinic with 40°C fever and joint pain, they don’t have time for diagnostic limbo. They need answers in 15 minutes. Our test delivers that. And that’s why we do this.
Order samples or request wholesale pricing: sales@testsealabs.com
Angela Qin
International Sales Director · Hangzhou Testsea Biotechnology Co., Ltd. (Testsealabs)
Founded 2015 — Serving society, health world. With over a decade of experience in the in vitro diagnostic and veterinary rapid test industry, Angela has built Testsealabs into a company that now serves customers in more than 100 countries worldwide. Her specialization is rapid diagnostic products — particularly those addressing infectious disease and vector-borne pathogens — and she has worked directly with clinicians, public health officials, and NGO procurement teams across Southeast Asia, Latin America, Africa, and the Middle East.
References and External Citations
- World Health Organization. (2024). Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. WHO/TDR
- Pan American Health Organization. (2025). Chikungunya Virus in the Americas. PAHO Epidemiological Update
- World Health Organization. (2023). Global Dengue Risk: Geographic Distribution and Expansion. WHO Global Health Estimates
- Instituto Butantan. (2025). Cross-reactivity Study: Zika IgM Detection in Dengue-endemic Regions. [Study data on file, Testsealabs.]
Post time: Jun-09-2026